Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get two FREE E-Books

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Depression: 21st Century Solutions + The Dark Side of Wheat

n/a

Why You Don't See Ads on GreenMedInfo

Did you know that GreenMedInfo.com is 100% member supported? It is through your membership that we are able to add research content daily, provide thoughtful articles on groundbreaking health & wellness topics, and continue to educate and empower people on the science supporting natural healing.

Our website has always offered open access to our carefully curated research (and always will) but we recently made the decision to become completely advertisement free.

In order for us to continue, we need your support more than ever. Our memberships start at only $8.00 per month and provide you with enhanced content & features.

We appreciate you supporting our mission and sharing our passion!

For more information on becoming a member of GreenMedInfo.com, click here.

Abstract Title:

Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma UnderExtracts After Resistance to R-CHOP: A Case Report.

Abstract Source:

Anticancer Res. 2018 Sep ;38(9):5363-5369. PMID: 30194190

Abstract Author(s):

Johannes Gutsch, Paul G Werthmann, Andreas Rosenwald, Gunver S Kienle

Article Affiliation:

Johannes Gutsch

Abstract:

BACKGROUND: A nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a lymphoproliferative neoplasm with a fair prognosis, but the possibility of a malignant transformation into a diffuse large B-cell lymphoma (DLBCL) is high. DLBCL progresses aggressively. Introduction of rituximab into therapy had led to improved outcomes. The use of Viscum album extracts (VAE) in cancer is established, but their application in lymphoma are rare.

CASE PRESENTATION: A 65-year-old patient was diagnosed with DLBCL stage IIa with splenomegaly, transformed from a NLPHL, after a 30-year history of repeatedly enlarged inguinal lymph nodes. The patient initially rejected chemotherapy. After his tumor pain increased, he accepted the consecutive therapies bendamustine plus vincristine plus prednisolone, trofosfamide, and rituximab plus cyclophosphamide plus hydroxydaunorubicin plus vincristine plus prednisone (R-CHOP), inducing only a slight regression of the splenic lesions. VAE was additionally applied to R-CHOP. Five months after termination of chemotherapy - under continued VAE therapy in increasing dosage- regression of paraaortal lesions was found. The patient fully recovered under continuous VAE application and is in ongoing complete remission and in a good state of health 17 years after the initial diagnosis.

CONCLUSION: As complete remission of lymphoproliferative disorders after VAE treatment has been previously reported, further investigations of VAE in lymphoma seem highly worthwhile.

Study Type : Human: Case Report
Additional Links
Pharmacological Actions : Chemotherapeutic : CK(397) : AC(152)

Print Options


Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get two FREE E-Books

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Depression: 21st Century Solutions + The Dark Side of Wheat

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2018 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.